Researchers have shown that a spinal cord-stimulating implant, originally used for paralysis, may help restore muscle ...

Contrary to prior data, this study shows that neither eosinophils nor STAT6-mediated IL-4/IL-13 signaling contribute ...

Patient advocate Austin Leclaire, who died Feb. 1, played a pivotal role in spurring the development of the first medicines ...

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) released topline results from its Phase 2 FIGHT DMD trial. The study evaluated ...

Despite the obstacles, Riley Herrera had a life filled with family, sports, travel, faith and hope before his death on Nov.

Edgewise Therapeutics , Inc. (NASDAQ:EWTX), with a market capitalization of $2.67 billion, is a biopharmaceutical company focused on developing innovative therapies for severe, rare muscle disorders.

Percheron Therapeutics says it will abandon its lead drug candidate altogether, following December's Duchenne muscular dystrophy trial flop.

High-dose treatment with the therapy was found to cause a 3.3% overall improvement in left ventricular ejection fraction.

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares began Tuesday sharply higher. Cumberland, a specialty pharmaceutical company with development efforts focused on new products for rare diseases, ...

Cumberland Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug has improved the amount of blood pumped by the heart, ...

Barbara Goodfriend, 83, opted for medical aid in dying after being diagnosed with ALS. The New Jersey widow ended her life in ...